A randomized phase 2 trial demonstrates that primary prophylaxis with peg-GCSF significantly reduces grade 3-4 and febrile neutropenia in patients with unresectable pancreatic cancer receiving mFOLFIRINOX, while improving patient-reported quality of life without increasing bone pain.